文献速递肝病消化道肿瘤与早癌

肝细胞癌肝移植前使用免疫检查点抑制剂的安全性

Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma.
PubMed 文献 · Aliment Pharmacol Ther · 2026-02-04

多中心回顾性队列研究纳入48例肝移植前接受免疫检查点抑制剂(ICI)的肝细胞癌患者,并按1:3倾向评分匹配144例未接受ICI的对照。ICI组排斥反应率18.8%,与对照组的19.4%无显著差异;排斥均获控制,无排斥相关死亡,总生存无差异。

要点

  • 肝移植前使用ICI的排斥率为18.8%,与未使用ICI者(19.4%)无显著差异。
  • 发生排斥者洗脱期更短(p=0.029),排斥均经治疗控制,无排斥相关死亡。
  • ICI组与非ICI组在移植物失败、HCC复发或总死亡率上无显著差异。

核心结论

  • 肝移植前接受ICI的患者排斥率与未接受ICI者相似,且排斥反应可安全处理。

研究设计与样本

  • 多中心回顾性队列研究,2018年1月至2024年12月,ICI组48例,倾向评分匹配1:3非ICI对照组144例。

主要发现

  • ICI组排斥反应9例(18.8%),均经活检证实,中位发生时间为移植后31天(12.0-182.0)。
  • 发生排斥者中位洗脱期60天(13-96),排斥者洗脱期更短(p=0.029)。
  • 5例HCC复发患者中60%接受ICI治疗不足90天(p=0.027)。
  • ICI组与非ICI组排斥率分别为18.8%与19.4%(p=0.916),移植物失败、HCC复发或总死亡率无显著差异。
  • 总生存(OS)在ICI与非ICI患者间(p=0.625)及有无排斥者间(p=0.119)均无显著差异。

临床怎么用

  • 肝移植前使用ICI需关注排斥风险,尤其洗脱期较短者,但排斥反应总体可控。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors (ICIs) have emerged as promising agents for the management of advanced HCC. By reducing tumour burden, ICIs may serve as a downstaging/bridging tool to improve transplant candidacy. The aim of this study was to assess the safety of patients receiving pre-LT ICIs. METHODS: Multicenter, retrospective cohort study from January 2018 to December 2024, including 48 patients who received ICIs prior to LT (ICI cohort). A control cohort (non-ICI cohort) was built (1:3) using propensity score matching including 144 patients who underwent LT for HCC without prior ICI. RESULTS: Within the ICI cohort (N = 48) rejection occurred in 9 patients (18.8%), all biopsy-proven, with a median onset of 31 days post-LT (12.0-182.0). The median washout period was 60 days (13-96). Patients experiencing rejection had shorter washout periods (p = 0.029). All rejection episodes were successfully managed; two were steroid-resistant, one requiring re-transplantation. There were no rejection-related deaths. Of the 5 patients with HCC recurrence, 60% received ICI for < 90 days (p = 0.027). Comparison between the ICI and non-ICI cohort revealed no significant differences in rejection rates (18.8% vs. 19.4%, p = 0.916), graft failure, HCC recurrence, or overall mortality. Overall survival (OS) did not differ between ICI and non-ICI patients (p = 0.625) or between those with and without rejection (p = 0.119). Rejection was not associated with increased mortality, with deaths primarily attributed to infection or HCC recurrence. CONCLUSION: Our results demonstrate that rejection rates were similar in patients receiving ICIs pre-LT and it can be safely managed.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Aceituno L, Magyar C, Tabrizian P, et al. Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma. Aliment Pharmacol Ther. 2026. PMID: 41640254. doi:10.1111/apt.70528

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。